Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
As additional FDA submissions and real-world studies emerge, further clarification of optimal dosing strategies and sustained efficacy will shape its role in future metabolic treatment protocols
When we add together the revenues of Ozempic, Mounjaro, Wegovy, and Zepbound, Lilly took over the market leader position since Q2 2025 with a 56% market share despite the fact that Zepbound is still hardly available outside the US and has negligible revenue in those regions
New England Journal of Medicine , 2015;373(1):11-22
The GLP-1 component offsets the blood sugar concern while the glucagon component drives metabolic rate higher
US$ 21.30
US$ 27.08
US$ 25.34
US$ 22.00
US$ 28.18
US$ 29.08
US$ 22.66
